Full metadata record
DC FieldValueLanguage
dc.creatorArenas, F. (Fabián)-
dc.creatorHervias, I. (Isabel)-
dc.creatorUriz, M. (Miriam)-
dc.creatorJoplin, R. (Ruth)-
dc.creatorPrieto, J. (Jesús)-
dc.creatorMedina, J.F. (Juan Francisco)-
dc.date.accessioned2012-07-17T12:17:11Z-
dc.date.available2012-07-17T12:17:11Z-
dc.date.issued2008-
dc.identifier.citationArenas F, Hervias I, Uriz M, Joplin R, Prieto J, Medina JF. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 2008 Feb;118(2):695-709.es_ES
dc.identifier.issn0021-9738-
dc.identifier.urihttp://hdl.handle.net/10171/22907-
dc.description.abstractPrimary biliary cirrhosis (PBC) is a cholestatic disease associated with autoimmune phenomena and alterations in both biliary bicarbonate excretion and expression of the bicarbonate carrier AE2. The bile acid ursodeoxycholic acid (UCDA) is currently used in treatment of cholestatic liver diseases and is the treatment of choice in PBC; however, a subset of PBC patients respond poorly to UDCA monotherapy. In these patients, a combination of UDCA and glucocorticoid therapy appears to be beneficial. To address the mechanism of this benefit, we analyzed the effects of UDCA and dexamethasone on AE2 gene expression in human liver cells from hepatocyte and cholangiocyte lineages. The combination of UDCA and dexamethasone, but not UDCA or dexamethasone alone, increased the expression of liver-enriched alternative mRNA isoforms AE2b1 and AE2b2 and enhanced AE2 activity. Similar effects were obtained after replacing UDCA with UDCA conjugates. In in vitro and in vivo reporter assays, we found that a UDCA/dexamethasone combination upregulated human AE2 alternate overlapping promoter sequences from which AE2b1 and AE2b2 are expressed. In chromatin immunoprecipitation assays, we demonstrated that combination UCDA/dexamethasone treatment induced p300-related interactions between HNF1 and glucocorticoid receptor on the AE2 alternate promoter. Our data provide a potential molecular explanation for the beneficial effects of the combination of UDCA and glucocorticoids in PBC patients with inadequate response to UDCA monotherapy.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society for Clinical Investigationes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAnion transport proteins/analysis/genetics/metabolismes_ES
dc.subjectAntiporters/analysis/genetics/metabolismes_ES
dc.subjectCell linees_ES
dc.titleCombination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cellses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1172/JCI33156es_ES
dc.type.driverinfo:eu-repo/semantics/articlees_ES

Files in This Item:
File: 
JCI 2008. 695.pdf
Description: 
Size: 
2,08 MB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.